MYGN EBITDA Growth
Myriad Genetics Inc · EBITDA Growth
MYGN EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported87.36%period ending
MYGN TTM EBITDA YoY % (-85.19% → 87.36%)
Year-over-year change
High-resolution chart · PNG
MYGN ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 87.3602% | |
| -423.0047% | |
| -457.0707% | |
| -595.9693% | |
| -282.8694% | |
| 63.3601% | |
| 69.9088% | |
| 76.1665% | |
| 53.9448% | |
| -66.2536% | |
| -133.0579% | |
| -184.2653% | |
| -2,485.8824% | |
| -474.6429% | |
| -788.6179% | |
| -227.9534% | |
| 146.9613% | |
| 139.4922% | |
| 108.0078% | |
| 137.0074% | |
| 87.1174% | |
| 20.2475% | |
| -428.2051% | |
| -359.84% | |
| -265.2941% | |
| -191.2731% | |
| -52.9175% | |
| -33.3689% | |
| -49.9411% | |
| -44.9095% | |
| -42.3434% | |
| -48.062% | |
| 74.6914% | |
| 66.4783% | |
| 29.2354% | |
| 14.5939% | |
| -49.8452% | |
| -45.3448% | |
| -28.5902% | |
| -11.1156% | |
| 21.8033% | |
| 10.9817% | |
| -2.5763% | |
| -24.5131% | |
| -44.8042% | |
| -41.1788% | |
| -35.866% | |
| -13.4453% | |
| 21.6859% | |
| 36.3277% | |
| 44.6902% | |
| 38.0603% | |
| 25.0824% | |
| 19.0297% | |
| 15.6627% | |
| 14.7687% | |
| 14.7827% | |
| 14.109% | |
| 17.4366% | |
| 15.7099% | |
| 16.0659% | |
| -9.8248% | |
| -15.9179% | |
| -17.9217% | |
| -13.535% | |
| 13.2749% | |
| 58.4655% | |
| 150.6623% | |
| 250.8483% | |
| 593.7935% | |
| 441.0449% | |
| 624.5188% | |
| 368.6214% | |
| -64.5838% | |
| -49.0296% | |
| 68.5167% | |
| 54.9609% | |
| 42.6269% | |
| 31.3049% | |
| -28.3959% | |
| -11.7771% | |
| 8.5834% | |
| 12.6669% | |
| 8.9125% | |
| 6.0132% | |
| -9.3149% | |
| -29.6537% | |
| -43.031% | |
| -67.0473% | |
| -53.8695% | |
| -41.8025% | |
| -53.0704% | |
| -55.8312% | |
| -111.5007% | |
| -115.6714% | |
| -89.2424% | |
| -50.5473% | |
| -8.7071% | |
| 0.5047% | |
| -2.3363% |